SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new mechanism-based TREM-1 therapy for acute respiratory distress syndrome

SignaBlok > News > SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new mechanism-based TREM-1 therapy for acute respiratory distress syndrome

SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new mechanism-based TREM-1 therapy for acute respiratory distress syndrome

Web Admin

View posts by Web Admin
Scroll to top